Table 2. Comparisons of the available meta-analyses evaluating the relationship between androgen deprivation therapy (ADT) and cardiovascular (CV) or thromboembolic risk cognitive impairment.

Inclusion criteria		Nguyen et al (2011) [41]		Carneiro et al (2015) [42]		Zhao et al (2014) [43]		Bosco et al (2015) [44]		Meng et al (2016) [45]		Poorthuis et al (2017) [46]		Liang et al (2020) [47]		Jin et al (2016) [48]
	No. of trials included	8		13		7		8		6		4		5		6
	No. of patients analyzed	2,200		60,696		129,802		189,202		74,538		NR		170,851		4,180
	No. of controls analyzed	1,941		83,001		165,605		274,810		85,947		NR		256,794		-
	Observational studies			×		×		×
	Randomized controlled studies	×		×										×
	Mixed population			×						×		×		×		×
Outcomes evaluated		Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
	CV death	×		×		×			×		×		×		×	×
	Acute myocardial infarction		×	×			×	×			×		×	×			×
	CV events		×	×		×		×			×		×		×	×
	Coronary heart diseases		×		×		×		×		×		×	×			×
	Sudden death		×		×		×		×		×		×	×			×
	Stroke		×	×			×	×		×		×			×		×
	ADT subtype analysis		×		×			×		×		×		×			×
	Continuous vs. intermittent ADT		×		×		×		×		×		×		×	×
Inclusion criteria		Guo et al (2018) [56]								Nead et al (2018) [57]
	No. of trials included	5								10
	No. of patients analyzed	170,851								32,409
	No. of controls analyzed	256,794								48,159
Outcomes evaluated		Yes				No				Yes				No
	Deep venous thrombosis	×												×
	Pulmonary embolism	×												×
	Overall thromboembolic events					×				×
	ADT subtype analysis	×								×

NR: not reported.